Developing R&D Strategy for Industrial Goods

Posted by Fuld + Company on Mar 31, 2016 4:48:40 PM

For companies developing an R&D strategy in industrial goods and infrastructure, competitive intelligence provides unique insights into competitors’ existing and potential R&D interest, capabilities, technology bets, and expected outcomes. Comparing rival R&D strategies to market needs and expectations provides a reality check on the feasibility and potential value of your future R&D programs. 

Strategic planning integrated with competitive and market intelligence can:

Read More

Topics: Competitive Intelligence, Product Roadmap, Fuld + Company, Manufacturing/Industrial, Market Analysis, Merger and Acquisition, Competitive Strategy

Defending Market Share in Pharma

Posted by Fuld + Company on Mar 18, 2016 9:49:49 AM

Pharmaceutical firms frequently need to defend their market position against rivals’ competitive strategy. Threats to leading therapies can come in many forms:

Read More

Topics: Competitive Intelligence, Fuld + Company, Pharma, Healthcare, Life Cycle Management, Life Sciences, Competitive Strategy

Meeting Emerging Competitive Threats Head On

Posted by Fuld + Company on Feb 29, 2016 3:50:55 PM

For companies needing to understand, and potentially neutralize, an emerging competitive threat, sound competitive intelligence (CI) lays the foundation for unbiased strategic advice.

CI clarifies the nature and severity of the challenge so that you can develop actionable contingency plans and counter-measures to dampen the impact of the emerging threat before it fully materializes.  

Emerging competitive threats can take many forms:

Read More

Topics: Competitive Intelligence, Fuld + Company, Innovation, Market Analysis, Scenario Analysis, Competitive Strategy

New White Paper: Navigating Risks in Emerging Economies

Posted by Fuld + Company on Feb 19, 2016 10:53:04 AM

Emerging markets present unique competitive challenges. While companies may account for obvious obstacles such as institutional voids and evolving infrastructure, they can fall victim to subtle cultural differences by neglecting to complete on-the-ground research prior to expansion. Local competition knows the rules of the game better than even the most savvy international firm.

Packed with exemplary successes and cautionary tales, our newest white paper - authored by Nathaniel Emmons, Director, Diversified practice - lays out the need for a systematic approach when entering frontier economies. Based on insights from security experts and seasoned investors, the paper offers a four part framework for identifying, analyzing, and reacting to risks and includes an Overseas Expansion Checklist.

To add real-world applicability, the paper focuses on bureaucratic hurdles, political risks, and security issues in diverse African and Asian countries:

Read More

Topics: Competitive Intelligence, Consumer Goods, Early Warning Monitoring, Manufacturing/Industrial, Market Analysis, New Market Entry, Scenario Analysis, Travel/Hospitality, Competitive Strategy

Upcoming Event: Fuld + Co. at Pharma CI Europe 2016 Conference & Exhibition

Posted by Fuld + Company on Feb 1, 2016 10:17:25 AM

Join us this month at Pharma CI Europe Conference & Exhibition taking place February 18-19th at the Charles de Gaulle Airport Marriott Hotel in Paris, France.

The Pharma CI Conference & Exhibition is the largest assembly of senior level pharma, biotech, and device professionals seeking the latest news and the chance to network with all the industry’s luminaries. 

Members of our Life Sciences team will be at our booth to find out how we can address your competitive intelligence and strategy development needs in the pharmaceutical, biotech, medical device, and diagnostics industries. David Staknis, Ph.D., Principal, Global Life Sciences Practice Head will be giving a talk on Protecting Institutional CI Memory on Friday, February 19th (details after the jump). 

Read More

Topics: Competitive Intelligence, Events, Fuld + Company, Life Sciences, Competitive Strategy

Leonard Fuld in HBR: Only Half of Companies Actually Use the Competitive Intelligence They Collect

Posted by Fuld + Company on Jan 28, 2016 2:50:55 PM

In his most recent Harvard Business Review article, charman and founder Leonard Fuld joins Ben Gilad, president and co-founder of the Fuld-Gilad-Herring Academy of Competitive Intelligence (ACI), to assess the impact of CI on major company decisions.

Based on a survey of 236 CI managers and analysts across 21 industries, Fuld and Gilad found that 55% of respondents said "their input on major management decisions made enough difference to improve the decision," leaving 45% whose analysis was ineffective at influencing executive decision making. 

When CI analysts were effective, four variables played a significant role: 

Read More

Topics: Competitive Intelligence, FGH Academy of Competitive Intelligence, Fuld, Leonard, Competitive Strategy

Medical Education and the Affordable Care Act

Posted by Fuld + Company on Jan 28, 2016 10:32:17 AM

Ken Sawka   | Jacob Golbitz 

Perhaps it was inevitable. Kaiser Permanente, the California-based health system that integrates health insurance with its own hospitals and clinics, last month announced that it would open its own medical school in the state in 2019. 

The move underscores two factors that have bedeviled healthcare reform in the United States before and after the passage of the Affordable Care Act in 2010 – a forecasted shortage of physicians in the United States, and the failure of traditional medical education to keep pace with the training required to enable physicians to provide healthcare in an integrated, risk-based system.

Read More

Topics: Competitive Intelligence, Innovation, Market Analysis, Healthcare, Life Sciences

New Video! Building a Life Sciences CI Team

Posted by Fuld + Company on Dec 15, 2015 9:50:08 AM

Finding the right talent to fill CI needs at a Life Sciences company can be challenging. From companion diagnostics to biosimilars, it's a complex marketplace that requires highly skilled CI practitioners.

David Staknis, Principal, Practice Head Global Life Sciences, and Ken Sawka, CEO + President, discuss necessary industry experience and academic qualifications for inclusion in a CI team, as well as team dynamics within Fuld + Company's own Life Sciences practice.

Read More

Topics: Competitive Intelligence, Fuld + Company, Pharma, Healthcare, Life Sciences

Fuld + Company and Agromeris Partner to Expand Services for Food and Agriculture Industry

Posted by Fuld + Company on Dec 14, 2015 8:00:00 AM


FOR IMMEDIATE RELEASE

BOSTON, MA, December 14, 2015 -- Fuld + Company, a competitive intelligence, strategy, and consulting firm, announced that it has signed a memorandum of understanding with Agromeris, a food and agriculture consulting firm.

The partnership provides Agromeris with methodological expertise and research capacity, drawn from Fuld + Company's 35+ years of experience. Agromeris brings to the partnership 30 years of deep domain expertise across the entire food production value chain, from field to table.

Read More

Topics: Competitive Intelligence, Consumer Goods, Fuld + Company, Manufacturing/Industrial, Market Analysis, Scenario Analysis, Product Positioning, Competitive Strategy

New Video! Companion Diagnostics

Posted by Fuld + Company on Dec 11, 2015 8:00:00 AM

Companion diagnostic (CDx) devices are in vitro and imaging tools that are paired with specific drug therapies. Part of a larger trend towards personalized medicine, they are used to identify patients most likely to benefit from a specific therapeutic agent or to determine appropriate dosage. 

While questions remain about who should bear the cost for companion diagnostics, the promise of greater safety and efficacy and the potential for faster regulatory approval have made this an area of growth for both pharmaceutical and molecular diagnostics clients.

David Staknis, Principal, Practice Head Global Life Sciences, and Ken Sawka, CEO + President, discuss increased requests for monitoring development and expansion of CDx platforms, earlier coordination by pharmaceutical and diagnostics firms, and the benefits of CI for optimizing R&D spending.

Read More

Topics: Competitive Intelligence, Early Warning Monitoring, Medical Devices, Pharma, Healthcare, Life Sciences

Fuld + Company Blog

The material on this page draws on the research and experience of Fuld + Company thought leaders, consultants and others. Learn more about our expertise here.

Recent Posts

Request for Information

If you'd like someone at Fuld to contact you regarding your strategic competitive challenges, fill out the form below.